Four-year follow-up data from the University of Edinburgh’s MATCH study, led by Resolution Therapeutics’ founder Professor Stuart Forbes, published in…
Study met its primary objective demonstrating excellent safety and tolerability, of RESP-X in patients with NCFB colonised with Pseudomonas aeruginosa (Pa)Secondary…
NORWALK, Conn., May 18, 2026 /PRNewswire/ -- Lifespan Vision Ventures (LVV), an investment firm focused on therapeutics that improve human…
May 17, 2026 16:00 ET | Source: Design Therapeutics, Inc. CARLSBAD, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics,…
- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast Track designation, in advanced ovarian…
Agoura Hills, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) (“Oncotelic” or the “Company”), a clinical-stage…
ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market >$100 billion.Inflammasome…
European Hematology Association (EHA) oral presentation to report 67% hematological improvement, durable transfusion independence, and no treatment-related serious adverse events…
May 08, 2026 20:45 ET | Source: Amplia Therapuetics Limited Melbourne, Australia, May 08, 2026 (GLOBE NEWSWIRE) -- HIGHLIGHTS Amplia…
LONDON, April 30, 2026 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a Kyowa Kirin company, announced it has been granted Innovation Passport…